

Lexaria Bioscience Corp.

07:40 13 Aug 2019

Lexaria Bioscience secures cannabis R&D license from Health Canada

Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP) said Tuesday that its subsidiary, Lexaria CanPharm ULC, has been issued a cannabis research and development (R&D) license by Health Canada.

In a statement, the company said that the license, which is effective immediately, has a four-year term until August 9, 2023 unless renewed.

The company pointed out that that the license will allow one of Canada's newest and most advanced formulation labs to carry out investigatory work in both THC and CBD delivery. The lab is fully rigged with the latest equipment needed to produce DehydraTECH infusions, it added.

READ: Lexaria Bioscience reveals exciting new findings from DehyraTECH study

The Kelowna, British Columbia-based company's novel drug-delivery platform, masks unwanted tastes, improves onset speed and increases the bioavailability of active pharmaceutical ingredients in a simple and cost-effective platform.

It allows drugs and vitamins — in the case of cannabis, CBD and THC — to enter the bloodstream faster than existing drug delivery platforms.

Previously, Lexaria used third-party agencies and institutions to conduct much of its R&D with controlled substances. The new lab, where Lexaria now has a new full-time PhD research scientist, will drive forward many R&D programs which have already been designed on paper.

In a statement, John Docherty, who is the chief scientist at Lexaria said: "Receipt of our R&D license from Health Canada will allow us to implement and complete investigatory studies significantly more rapidly now, than at any previous time in our company's history."

Docherty also noted that the license will "greatly enhance" the lab's ability to work with cannabis licensed producers to perform work in-house on customized formulations that could Canadian cannabis companies.

Lexaria shared its R&D blueprint, saying its lab will focus on producing and evaluating topical creams and lotions, orally-ingested product formats for delivery of active ingredients including THC, CBD, NSAID's such as ibuprofen, PDE5-inhibitors such as those used in Viagra; nicotine and other molecules.

Contact Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Price: 0.41

Market Cap: \$33.1 m

1 Year Share Price Graph



April 2019 September 2019 March 2020

Share Information

Code: LXX

Listing: CSE

52 week	High	Low
	1.59	0.32

Sector: Cannabis

Website: www.lexariabioscience.com

Company Synopsis:

Lexaria Bioscience Corp has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules. Many vitamins, drugs, supplements and other beneficial molecules are lipophilic (i. e.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).